Skip to content

Wear and Migration in the Corin Mini-Hip/Metafix and ECIMA Polyethylene

RSA-measured in Vivo Wear, Migration and Micromotion in the Corin Mini-Hip/Metafix and ECIMA Polyethylene.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02174965
Acronym
MiniHip
Enrollment
50
Registered
2014-06-26
Start date
2012-09-30
Completion date
2022-09-30
Last updated
2014-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Osteoarthritis

Brief summary

The primary objective of this study is to determine whether the Mini Hip (Corin, U.K.) femoral component has a predictable and stable migration pattern (mean migration of the femoral component in three-dimensions,in mm) over a three year period, compared to a conventional cementless stem (Metafix, Corin, U.K.). The secondary objectives of this study are to determine whether the Trinity (Corin, U.K.) acetabular component has a predictable and stable migration pattern over a three year period and to measure the linear wear of femoral head into the ECIMA Highly Cross-linked polyethylene.

Interventions

DEVICEMiniHip (Corin U.K.)

MiniHip (Corin U.K.) femoral component

DEVICEMetafix (Corin, U.K)

Metafix (Corin, U.K) conventional cementless stem

Sponsors

Corin
CollaboratorINDUSTRY
Oxford University Hospitals NHS Trust
CollaboratorOTHER
University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Women and men between the ages of 18 and 65 years old. * Scheduled to receive a hip replacement * Willing and able to give informed consent for participation in the study. * Diagnosed with hip osteoarthritis * Able (in the investigators opinion) and willing to comply with all study requirements. * Willing to allow his/her General Practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion criteria

The participants may not enter the study if ANY of the following apply: * Inflammatory arthropathy, osteoporosis or deformities of the proximal femur. * Significant comorbidities that would make follow up difficult or uncomfortable * Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk due to participation in the study, may influence the result of the study, or the participants ability to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Radiostereometric Analysis (RSA) measured migration (mm)Measured pre-operatively (baseline) and at 3, 6, 12, 18, 24 and 36 months post-operativelyThe images taken at each time point will be compared with the baseline to assess implant migration. Therefore the outcome is change in implant position measured using RSA.

Secondary

MeasureTime frameDescription
Dynamically Inducible Micromotion DIMM (mm)Measured at 6, 12, 24 and 36 months post-operativelyUsing RSA this compares standard images with images taken in a single leg stance.
Implant failure for femoral and acetabular componentsObserved at 3, 6, 12, 18, 24 and 36 months post-operativelyFollow up assessment will monitor for signs of implant failure.
Change in Oxford Hip ScoreMeasured pre-operatively (baseline) and at 3, 6, 12, 18, 24 and 36 months post-operativelyA PROM to assess patient benefit.
Change in Harris Hip ScoreMeasured pre-operatively (baseline) and at 3, 6, 12, 18, 24 and 36 months post-operativelyA clinician recorded outcome score to assess functional improvement.

Other

MeasureTime frameDescription
DEXA ScanPre-operatively (baseline) and at 12 months post-operativelyTo monitor for peri-prosthetic changes in bone density following surgery

Countries

United Kingdom

Contacts

Primary ContactJohn Broomfield
john.broomfield@ndorms.ox.ac.uk
Backup ContactAlice Harin
alice.harin@ouh.nhs.uk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026